Book Now
A new weight-loss drug has been approved by the F.D.A and is expected to hit the market soon. The drug, Zepbound, is a once a week injectable prescription medication developed by Eli Lilly, the same makers of the diabetes drug, Mounjaro. Like Mounjaro, Zepbound contains the compound tizepatide. Mounjaro was first approved in 2022 for type 2 diabetics looking to lower their A1C levels and potentially lose weight. While weight-loss drugs and injectables can be an effective short-term strategy, the long-term success and tolerance for side effects of these medications is still being researched.
Differences Between Zepbound and Other Weight-loss Drugs
Zepbound is the second drug to be approved for weight loss, following Wegovy. Like semaglutide, found in Ozempic and Wegovy, tirzepatide slows down the emptying of the stomach, leaving a person feeling fuller, longer.
All three drugs target the area of the brain that curbs food cravings for many people, the hypothalamus. However, Zepbound is the first dual-acting weight-loss drug that activates the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) hormone receptors. Targeting the GLP-1 receptor reduces food intake, appetite and hunger, and promotes fullness and satiety. Targeting the GIP receptor also stimulates satiety in the hypothalamus. Semaglutide only activates one of these receptors, GLP-1. This dual combination is believed to help people lose more weight. Eli Lilly found that patients with an average starting weight of 231 pounds lost 48 pounds taking the lowest dose and 58 pounds taking the highest dose of Zepbound
Who Can Take Zepbound?
The F.D.A. approved the once a week use of Zepbound for people with a body mass index (B.M.I.) of 30 or greater or those with a B.M.I. of 27 or greater with weight-related conditions like high blood pressure, type 2 diabetes, or sleep apnea.
Common Side Effects
Weight-loss drugs and injectables are gaining popularity, but there can be potential side effects for some patients that can be managed by a doctor-supervised medical weight-loss program.An Eli Lilly funded study found that gastrointestinal issues were the most common side effects of Zepbound. Study participants experienced nausea, constipation, headache, and dizziness.
While weight-loss drugs and injectables can be an effective short-term strategy, the long-term success and tolerance for side effects of these medications is still being researched.
New York Bariatric Group: Weight Loss Leader
New York Bariatric Group’s doctor-supervised medical weight loss program is committed to patient safety and well-being. Patients benefit from regular monitoring and follow-up appointments. This ongoing supervision allows doctors to make necessary adjustments to a patient’s treatment plan based on their progress and any changes in their health status. It ensures that the weight loss journey is personalized and optimized for each individual, leading to more effective outcomes.
New York Bariatric Group is a leader in long-term weight-loss solutions. Their bariatric practice is the best around and they have the numbers to prove it:
- Over 30 surgeons who are leaders in bariatrics, plastic surgery, veins, and medical weight loss
- 42,000 successful procedures performed, with more every day
- The #1 gastric balloon practice by volume – most balloons placed in the United States
- Access to online seminars, support groups, cooking demos, and Q-and-A sessions
- 100s of videos for patients explaining procedures, answering common questions, and
showcasing previous patients - Multiple offices located in three states; NY, NJ, CT
- Since 2000, we boast over 23 years of success!
All of our hospitals are Metabolic Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) accredited facilities, which is a prestigious designation bestowed upon only the top-quality bariatric programs.
Stop waiting; start achieving better health today. Together, we’ve got this!
New York Bariatric Group is implementing and enforcing strict guidelines put out by the Center of Disease Control and the Department of Health in order to keep our staff and patients safe.
We are offering in-person and virtual consultations to ensure that everyone is able to get the information and care they deserve without feeling pressure to leave their home.
